Pulmonary Arterial Hypertension Market

Market Study on Pulmonary Arterial Hypertension: Revenue would Increase 1.8X times between 2022 and 2032, Reaching Roughly US$ 13.7 Bn in 2032

Pulmonary Arterial Hypertension Market Segmentation by Drug Class - Endothelin Receptor Antagonists | PDE-5 Inhibitors | Prostacyclin and Prostacyclin Analogs | SGC Stimulators

Industry: Healthcare

Published Date: November-2022

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Number of Pages: 250

Report Price

$4900*

Buy Now
Get Customisation

Report ID: PMRREP33199

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

    3.1. Risk Assessment

        3.1.1. COVID-19 Crisis and Impact on Pulmonary Arterial Hypertension Market

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis

        3.1.3. Impact on Market Value (US$ Bn)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background

    4.1. Pulmonary Arterial Hypertension Market, by Key Countries

    4.2. Pulmonary Arterial Hypertension Market Opportunity Assessment (US$ Bn)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Impact

        4.5.1. Top Companies Historical Growth

        4.5.2. Growth in Automation, By Country

        4.5.3. Microneedle Drug Delivery Systems Markets Adoption Rate, By Country

    4.6. Market Dynamics

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Microneedle Drug Delivery Systems Markets Market Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking

6. Global Pulmonary Arterial Hypertension Market Demand Analysis 2017-2021 and Forecast, 2022-2032

    6.1. Historical Market Analysis, 2017-2021

    6.2. Current and Future Market Projections, 2022-2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Pulmonary Arterial Hypertension Market Value Analysis 2017-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Bn) Analysis, 2017-2021

    7.2. Current and Future Market Value (US$ Bn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2017-2021

    8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2022-2032

        8.3.1. Endothelin Receptor Antagonists (ERAs)

        8.3.2. PDE-5 inhibitors

        8.3.3. Prostacyclin and Prostacyclin Analogs

        8.3.4. SGC Stimulators

    8.4. Market Attractiveness Analysis By Microneedle Drug Delivery Systems

9. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Bn) Analysis By Type, 2017-2021

    9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Type, 2022-2032

        9.3.1. Branded

        9.3.2. Generics

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2017-2021

    10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032

        10.3.1. Oral

        10.3.2. Intravenous/ Subcutaneous

        10.3.3. Inhalational

    10.4. Market Attractiveness Analysis By Route of Administration

11. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Bn) Analysis By Region, 2017-2021

    11.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2022-2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. Asia Pacific

        11.3.5. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    12.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032

        12.4.1. By Country

            12.4.1.1. U.S.

            12.4.1.2. Canada

        12.4.2. By Drug Class

        12.4.3. By Route of Administration

        12.4.4. By Route of Administration

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Type

        12.5.3. By Route of Administration

        12.5.4. By Route of Administration

13. Latin America Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    13.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032

        13.4.1. By Country

            13.4.1.1. Brazil

            13.4.1.2. Mexico

            13.4.1.3. Rest of Latin America

        13.4.2. By Drug Class

        13.4.3. By Route of Administration

        13.4.4. By Route of Administration

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By Route of Administration

        13.5.4. By Route of Administration

14. Europe Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    14.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Germany

            14.4.1.2. France

            14.4.1.3. U.K.

            14.4.1.4. Italy

            14.4.1.5. Spain

            14.4.1.6. Russia

            14.4.1.7. Rest of Europe

        14.4.2. By Drug Class

        14.4.3. By Route of Administration

        14.4.4. By Route of Administration

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By Route of Administration

        14.5.4. By Route of Administration

15. Asia Pacific Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    15.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. China

            15.4.1.2. Japan

            15.4.1.3. South Korea

            15.4.1.4. India

            15.4.1.5. Australia

            15.4.1.6. Rest of Asia Pacific

        15.4.2. By Drug Class

        15.4.3. By Route of Administration

        15.4.4. By Route of Administration

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By Route of Administration

        15.5.4. By Route of Administration

16. Middle East and Africa Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    16.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. Saudi Arabia

            16.4.1.2. South Africa

            16.4.1.3. Israel

            16.4.1.4. UAE

            16.4.1.5. Rest of Middle East and Africa

        16.4.2. By Drug Class

        16.4.3. By Route of Administration

        16.4.4. By Route of Administration

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Type

        16.5.3. By Route of Administration

        16.5.4. By Route of Administration

17. Key Countries Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

        17.1.1. Market Value Proportion Analysis, By Key Countries

        17.1.2. Global Vs. Country Growth Comparison

    17.2. US Pulmonary Arterial Hypertension Market Analysis

        17.2.1. Value Proportion Analysis by Market Taxonomy

        17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.2.2.1. By Drug Class

            17.2.2.2. By Route of Administration

            17.2.2.3. By Route of Administration

    17.3. Canada Pulmonary Arterial Hypertension Market Analysis

        17.3.1. Value Proportion Analysis by Market Taxonomy

        17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.3.2.1. By Type

            17.3.2.2. By Route of Administration

            17.3.2.3. By Route of Administration

    17.4. Mexico Pulmonary Arterial Hypertension Market Analysis

        17.4.1. Value Proportion Analysis by Market Taxonomy

        17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.4.2.1. By Drug Class

            17.4.2.2. By Route of Administration

            17.4.2.3. By Route of Administration

    17.5. Brazil Pulmonary Arterial Hypertension Market Analysis

        17.5.1. Value Proportion Analysis by Market Taxonomy

        17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.5.2.1. By Type

            17.5.2.2. By Route of Administration

            17.5.2.3. By Route of Administration

    17.6. Germany Pulmonary Arterial Hypertension Market Analysis

        17.6.1. Value Proportion Analysis by Market Taxonomy

        17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.6.2.1. By Drug Class

            17.6.2.2. By Route of Administration

            17.6.2.3. By Route of Administration

    17.7. France Pulmonary Arterial Hypertension Market Analysis

        17.7.1. Value Proportion Analysis by Market Taxonomy

        17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.7.2.1. By Drug Class

            17.7.2.2. By Route of Administration

            17.7.2.3. By Route of Administration

    17.8. Italy Pulmonary Arterial Hypertension Market Analysis

        17.8.1. Value Proportion Analysis by Market Taxonomy

        17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.8.2.1. By Drug Class

            17.8.2.2. By Route of Administration

            17.8.2.3. By Route of Administration

    17.9. India Pulmonary Arterial Hypertension Market Analysis

        17.9.1. Value Proportion Analysis by Market Taxonomy

        17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.9.2.1. By Drug Class

            17.9.2.2. By Route of Administration

            17.9.2.3. By Route of Administration

    17.10. UK Pulmonary Arterial Hypertension Market Analysis

        17.10.1. Value Proportion Analysis by Market Taxonomy

        17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.10.2.1. By Type

            17.10.2.2. By Route of Administration

            17.10.2.3. By Route of Administration

    17.11. Australia Pulmonary Arterial Hypertension Market Analysis

        17.11.1. Value Proportion Analysis by Market Taxonomy

        17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.11.2.1. By Drug Class

            17.11.2.2. By Route of Administration

            17.11.2.3. By Route of Administration

    17.12. China Pulmonary Arterial Hypertension Market Analysis

        17.12.1. Value Proportion Analysis by Market Taxonomy

        17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.12.2.1. By Drug Class

            17.12.2.2. By Route of Administration

            17.12.2.3. By Route of Administration

    17.13. Japan Pulmonary Arterial Hypertension Market Analysis

        17.13.1. Value Proportion Analysis by Market Taxonomy

        17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.13.2.1. By Drug Class

            17.13.2.2. By Route of Administration

            17.13.2.3. By Route of Administration

    17.14. South Korea Pulmonary Arterial Hypertension Market Analysis

        17.14.1. Value Proportion Analysis by Market Taxonomy

        17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.14.2.1. By Drug Class

            17.14.2.2. By Route of Administration

            17.14.2.3. By Route of Administration

    17.15. Israel Pulmonary Arterial Hypertension Market Analysis

        17.15.1. Value Proportion Analysis by Market Taxonomy

        17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.15.2.1. By Drug Class

            17.15.2.2. By Route of Administration

            17.15.2.3. By Route of Administration

    17.16. South Africa Pulmonary Arterial Hypertension Market Analysis

        17.16.1. Value Proportion Analysis by Market Taxonomy

        17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.16.2.1. By Drug Class

            17.16.2.2. By Route of Administration

            17.16.2.3. By Route of Administration

    17.17. UAE Pulmonary Arterial Hypertension Market Analysis

        17.17.1. Value Proportion Analysis by Market Taxonomy

        17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.17.2.1. By Drug Class

            17.17.2.2. By Route of Administration

            17.17.2.3. By Route of Administration

    17.18. Spain Pulmonary Arterial Hypertension Market Analysis

        17.18.1. Value Proportion Analysis by Market Taxonomy

        17.18.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.18.2.1. By Drug Class

            17.18.2.2. By Route of Administration

            17.18.2.3. By Route of Administration

    17.19. Russia Pulmonary Arterial Hypertension Market Analysis

        17.19.1. Value Proportion Analysis by Market Taxonomy

        17.19.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.19.2.1. By Drug Class

            17.19.2.2. By Route of Administration

            17.19.2.3. By Route of Administration

    17.20. Saudi Arabia Pulmonary Arterial Hypertension Market Analysis

        17.20.1. Value Proportion Analysis by Market Taxonomy

        17.20.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032

            17.20.2.1. By Drug Class

            17.20.2.2. By Route of Administration

            17.20.2.3. By Route of Administration

    17.21. Competition Landscape and Player Concentration in the Country

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies

    18.2. Market Concentration

    18.3. Market Share Analysis of Top Players

    18.4. Market Presence Analysis

        18.4.1. By Regional footprint of Players

        18.4.2. Product footprint by Players

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Competition Deep Dive

        19.3.1. United Therapeutics Corporation

            19.3.1.1. Overview

            19.3.1.2. Product Portfolio

            19.3.1.3. Sales Footprint

            19.3.1.4. Strategy Overview

        19.3.2. Bayer

            19.3.2.1. Overview

            19.3.2.2. Product Portfolio

            19.3.2.3. Sales Footprint

            19.3.2.4. Strategy Overview

        19.3.3. Johnson & Johnson

            19.3.3.1. Overview

            19.3.3.2. Product Portfolio

            19.3.3.3. Sales Footprint

            19.3.3.4. Strategy Overview

        19.3.4. Novartis

            19.3.4.1. Overview

            19.3.4.2. Product Portfolio

            19.3.4.3. Sales Footprint

            19.3.4.4. Strategy Overview

        19.3.5. Lupin Pharmaceuticals

            19.3.5.1. Overview

            19.3.5.2. Product Portfolio

            19.3.5.3. Sales Footprint

            19.3.5.4. Strategy Overview

        19.3.6. Viatris Inc.

            19.3.6.1. Overview

            19.3.6.2. Product Portfolio

            19.3.6.3. Sales Footprint

            19.3.6.4. Strategy Overview

        19.3.7. Sun Pharmaceutical Industries, Inc.

            19.3.7.1. Overview

            19.3.7.2. Product Portfolio

            19.3.7.3. Sales Footprint

            19.3.7.4. Strategy Overview

        19.3.8. Teva Pharmaceutical Industries Ltd.

            19.3.8.1. Overview

            19.3.8.2. Product Portfolio

            19.3.8.3. Sales Footprint

            19.3.8.4. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology

Sample Report

Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

List Of Table

Table 1: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 2: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 3: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 4: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 5: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 6: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 7: Global Pulmonary Arterial Hypertension Market, By Region, 2017 – 2021

Table 8: Global Pulmonary Arterial Hypertension Market, By Region, 2022 – 2032

Table 9: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 10: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 11: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 12: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 13: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 14: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 15: North America Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021

Table 16: North America Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032

Table 17: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 18: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 19: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 20: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 21: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 22: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 23: Latin America Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021

Table 24: Latin America Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032

Table 25: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 26: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 27: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 28: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 29: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 30: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 31: Europe Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021

Table 32: Europe Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032

Table 33: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 34: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 35: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 36: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 37: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 38: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 39: Asia Pacific Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021

Table 40: Asia Pacific Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032

Table 41: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021

Table 42: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032

Table 43: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021

Table 44: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032

Table 45: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021

Table 46: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032

Table 47: MEA Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021

Table 48: MEA Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032

Table 49: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 50: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 51: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021

Table 52: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Region, 2022 – 2032

Table 53: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 54: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 55: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 – 2021

Table 56: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 57: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 58: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 59: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021

Table 60: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 61: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 62: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 63: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021

Table 64: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 - 2032

Table 65: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 66: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 67: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021

Table 68: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 69: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021

Table 70: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 71: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021

Table 72: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 - 2032

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

- List Of Chart -

Figure 1: Global Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 2: Global Pulmonary Arterial Hypertension Market Absolute $ Historical Gain (2017 - 2021) and Opportunity (2022 – 2032), US$ Bn

Figure 3: Global Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 4: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 5: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 6: Global Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 7: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 8: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 9: Global Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 10: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 11: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 12: Global Pulmonary Arterial Hypertension Market Share, By Region, 2022 & 2032

Figure 13: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Region – 2022-2032

Figure 14: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Region – 2022-2032

Figure 15: North America Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 16: North America Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn

Figure 17: North America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 18: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 19: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 20: North America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 21: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 22: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 23: North America Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 24: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 25: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 26: North America Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032

Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 28: North America Market Attractiveness Index, By Country – 2022-2032

Figure 29: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 30: Latin America Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn

Figure 31: Latin America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 32: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 33: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 34: Latin America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 35: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 36: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 37: Latin America Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 38: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 39: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 40: Latin America Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032

Figure 41: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 42: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032

Figure 43: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 44: Europe Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn

Figure 45: Europe Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 46: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 47: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 48: Europe Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 49: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 50: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 51: Europe Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 52: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 53: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 54: Europe Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032

Figure 55: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 56: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032

Figure 57: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 58: MEA Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn

Figure 59: MEA Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 60: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 61: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 62: MEA Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 63: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 64: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 65: MEA Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 66: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 67: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 68: MEA Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032

Figure 69: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 70: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032

Figure 71: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032

Figure 72: Asia Pacific Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn

Figure 73: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032

Figure 74: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032

Figure 75: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032

Figure 76: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032

Figure 77: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032

Figure 78: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032

Figure 79: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032

Figure 80: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 81: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 82: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032

Figure 83: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 84: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032

Figure 85: US Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 86: US Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 87: US Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 88: US Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 89: Canada Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 90: Canada Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 91: Canada Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 92: Canada Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 93: Brazil Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 94: Brazil Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 95: Brazil Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 96: Brazil Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 97: Mexico Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 98: Mexico Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 99: Mexico Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 100: Mexico Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 101: Germany Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 102: Germany Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 103: Germany Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 104: Germany Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 105: U.K. Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 106: U.K. Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 107: U.K. Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 108: U.K. Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 109: France Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 110: France Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 111: France Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 112: France Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 113: Italy Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 114: Italy Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 115: Italy Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 116: Italy Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 117: India Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 118: India Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 119: India Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 120: India Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 121: Russia Countries Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 122: Russia Countries Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 123: Russia Countries Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 124: Russia Countries Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 125: China Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 126: China Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 127: China Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 128: China Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 129: Japan Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 130: Japan Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 131: Japan Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 132: Japan Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 133: South Korea Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 134: South Korea Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 135: South Korea Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 136: South Korea Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 137: Spain Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 138: Spain Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 139: Spain Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 140: Spain Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 141: South Africa Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 142: South Africa Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 143: South Africa Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 144: South Africa Pulmonary Arterial Hypertension Market Share, By Type, 2021

Figure 145: Saudi Arabia Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032

Figure 146: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021

Figure 147: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021

Figure 148: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Type, 2021

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate